APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctionalprotein that shows elevated expression in a number of cancers. We attempted to determinewhether serum APE1/Ref-1 is elevated in patients with bladder cancer. Materials and MethodsSerum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay inserum from patients with bladder cancer who had not received chemotherapy or radiotherapy(n=51) and non-tumor controls (n=55). The area under the receiver operating characteristicarea under the curve was applied to determine the correlation between clinicalfactors and the serum levels of APE1/Ref-1. ResultsSerum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated comparedto those of the control group (3.548±0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547±0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage,grade, muscle invasion, and recurrence. ConclusionSerum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.
Abstract
Purpose Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctionalprotein that shows elevated expression in a number of cancers. We attempted to determinewhether serum APE1/Ref-1 is elevated in patients with bladder cancer. Materials and MethodsSerum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay inserum from patients with bladder cancer who had not received chemotherapy or radiotherapy(n=51) and non-tumor controls (n=55). The area under the receiver operating characteristicarea under the curve was applied to determine the correlation between clinicalfactors and the serum levels of APE1/Ref-1. ResultsSerum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated comparedto those of the control group (3.548±0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547±0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage,grade, muscle invasion, and recurrence. ConclusionSerum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.
참고문헌 (24)
- Siegel R, "Cancer treatment and survivorship statistics, 2012", CA Cancer J Clin, 62, pp.220~241 (2012)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008", Cancer Research and Treatment, 43(1), pp.1~11 (2011), 대한암학회
- Lamm DL, "Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder : a randomized Southwest Oncology Group Study", J Urol, 163, pp.1124~1129 (2000)
- Vrooman OP, "Molecular markers for detection, surveillance and prognostication of bladder cancer", Int J Urol, 16, pp.234~243 (2009)
- Raab SS, "Urine cytology discrepancies : frequency, causes, and outcomes", Am J Clin Pathol, 127, pp.946~953 (2007)
- Brimo F, "Accuracy of urine cytology and the significance of an atypical category", Am J Clin Pathol, 132, pp.785~793 (2009)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)
- Sethi G, "Multifaceted link between cancer and inflammation", Biosci Rep, 32, pp.1~15 (2012)
- Zhang Y, "Alterations in the expression of the apurinic", apyrimidinic endonuclease-1, Ref-1)in human ovarian cancer and indentification of the therapeutic potential of APE1, pp.Ref-1inhibitor, Int J Oncol[DOI]
- Park MS, "Identification of plasma APE1", Ref-1 in lipopolysaccharideinduced endotoxemic rats : implication of serological biomarker for an endotoxemia, 2013, pp.435, 621~626
- Choi S, "Histone deacetylases inhibitor trichostatin A modulates the extracellular release of APE1", Ref-1, 2013, pp.435, 403~407
- Tell G, "The intracellular localization of APE1", Ref-1: more than a passive phenomenon?, 2005, pp.7, 367~384
- Tell G, "Understanding different functions of mammalian AP endonuclease(APE1)as a promising tool for cancer treatment", Cell Mol Life Sci, 67, pp.3589~3608 (2010)
- Puglisi F, "Prognostic role of Ape", Ref-1 subcellular expression in stage I-III breast carcinomas, 2002, pp.9, 11~17
- Dai N, "Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer", PLoS One, 8, pp.e58001~ (2013)
- Greene FL, "The American Joint Committee on Cancer : updating the strategies in cancer staging", Bull Am Coll Surg, 87, pp.13~15 (2002)
- Helpap B, "New WHO classification of urothelial carcinoma of the urinary bladder", Verh Dtsch Ges Pathol, 86, pp.57~66 (2002)
- Fluss R, "Estimation of the Youden Index and its associated cutoff point", Biom J, 47, pp.458~472 (2005)
- German RR, "The accuracy of cancer mortality statistics based on death certificates in the United States", Cancer Epidemiol, 35, pp.126~131 (2011)
- Offersen BV, "Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival", Acta Oncol, 49, pp.1283~1287 (2010)
- Qu J, "Nitric oxide controls nuclear export of APE1", Ref-1 through S-nitrosation of cysteines 93 and 310, 2007, pp.35, 2522~2532
- Grossman HB, "Detection of bladder cancer using a pointof-care proteomic assay", JAMA, 293, pp.810~816 (2005)
- Huber S, "Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study", BJU Int, 110, pp.699~708 (2012)
- Lai Y, "UPK3A: a promising novel urinary marker for the detection of bladder cancer", Urology, 76, pp.514.e6~514.e11 (2010)